tradingkey.logo
tradingkey.logo
Search

IDEAYA Biosciences Announces First-Patient-In for Phase 1 Trial of IDE574, a Potential First-In Class Dual Inhibitor of KAT6/7 to Target Multiple Solid Tumor Indications, including Breast, Prostate, CRC, and Lung Cancer

ReutersApr 6, 2026 10:46 AM

- IDEAYA Biosciences Inc IDYA.O:

  • IDEAYA BIOSCIENCES ANNOUNCES FIRST-PATIENT-IN FOR PHASE 1 TRIAL OF IDE574, A POTENTIAL FIRST-IN CLASS DUAL INHIBITOR OF KAT6/7 TO TARGET MULTIPLE SOLID TUMOR INDICATIONS, INCLUDING BREAST, PROSTATE, CRC, AND LUNG CANCER

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.
Tradingkey

Recommended Articles

Tradingkey
KeyAI